Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

Docetaxel (Taxotere®), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line treatment of metastatic breast cancer. This phase II study investigated the efficacy and tolerability of docetaxel as neoadjuvant chemotherapy in women with stage II–III pri...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Amat, S, Bougnoux, P, Penault-Llorca, F, Fétissof, F, Curé, H, Kwiatkowski, F, Achard, J-L, Body, G, Dauplat, J, Chollet, P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2003
Konular:
Clinical
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2741049/
https://ncbi.nlm.nih.gov/pubmed/12778058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600916
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller